Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trivalent influenza vaccine (split virion), inactivated (mdck cell)
- Development stage
- Unknown
- Lead developer
- Shenzhen Kangtai Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Trivalent influenza vaccine (split virion), inactivated (MDCK cell) is a seasonal influenza vaccine produced using cell-culture technology rather than traditional embryonated chicken eggs. Developed by Lanzhou Bailing Biotechnology and Shenzhen Kangtai Biological Products, the vaccine utilizes Madin-Darby Canine Kidney (MDCK) cells as a substrate for the propagation of influenza viruses. This method reduces the risk of egg-adaptive mutations that can compromise vaccine efficacy and makes the vaccine suitable for individuals with egg allergies. The trivalent formulation is designed to protect against three influenza strains: two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage. It is currently in Phase I clinical development in China to evaluate its safety and immunogenicity in individuals aged 3 years and older.
- Other names
- MDCK cell-based trivalent influenza split vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on trivalent influenza vaccine (split virion), inactivated (mdck cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trivalent influenza vaccine (split virion), inactivated (mdck cell).